Form 4: Metagenomi Therapeutics: CFO Equity Transactions

Metagenomi Therapeutics reports on equity transactions involving Chief Financial Officer Pamela Wapnick, including restricted stock units and stock options.

Summary

• Pamela Wapnick, Chief Financial Officer of Metagenomi Therapeutics, Inc., reported equity transactions on April 1, 2026.
• The transactions include the acquisition of 24,000 shares of Common Stock, which represent restricted stock units (RSUs).
• These RSUs have a vesting schedule: 25% vest on June 5, 2027, and the remainder vest in 12 equal quarterly installments thereafter, contingent on continued service.
• Additionally, a stock option for 144,000 shares was acquired with an exercise price of $1.34.
• This stock option vests 25% on April 1, 2027, with the remaining 75% vesting in 36 equal monthly installments thereafter, also contingent on continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports standard equity compensation for a key executive, which is typical for companies in this sector and does not inherently signal positive or negative performance.

Positives

• The CFO has been granted equity awards, indicating continued investment and alignment with the company's long-term performance.
• The vesting schedules for RSUs and stock options are structured to incentivize continued service and commitment to the company.

Risks

• Vesting of RSUs and stock options is contingent upon continued service, meaning any departure from the company before vesting dates would result in forfeiture of these awards.
• The stock option exercise price of $1.34 implies that the company's stock price needs to exceed this level for the options to be profitable.

Future Outlook

The future outlook is tied to the vesting schedules of the RSUs and stock options, which are dependent on the reporting person's continued service and the company's stock performance exceeding the option exercise price.

Industry Context

StockSavvy.ai notes that equity grants to key executives like the CFO are standard practice in the biotechnology and therapeutics sector to attract and retain talent, aligning their interests with long-term shareholder value.

Stakeholder Impact

• Shareholders: The equity grants align executive interests with long-term company performance, potentially benefiting shareholders if the company succeeds. However, dilution is a minor consideration with stock options.
• Employees: The CFO's equity awards are standard compensation and do not directly impact other employees, though company success driven by management can indirectly benefit all employees.
• Management: The CFO's compensation is directly tied to continued service and company performance through these equity awards.

Next Steps

• Continued service by Pamela Wapnick to meet vesting requirements for RSUs and stock options.
• Monitoring of Metagenomi Therapeutics' stock price relative to the $1.34 stock option exercise price.

Key Dates

Keywords

Metagenomi Therapeutics, MGX, Form 4, Pamela Wapnick, Chief Financial Officer, equity, restricted stock units, RSUs, stock options, vesting, SEC filing